Acura Pharmaceuticals | ACUR

Acura Pharmaceuticals traded at $0.01 this Monday September 19th, increasing $0.01 or 100.00 percent since the previous trading session. Looking back, over the last four weeks, Acura Pharmaceuticals gained 87.50 percent. Over the last 12 months, its price fell by 98.18 percent. Looking ahead, we forecast Acura Pharmaceuticals to be priced at 0.01 by the end of this quarter and at 0.01 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Shionogi 7,007.00 -61.00 -0.86% -6.57%
AcelRx Pharmaceuticals 0.21 -0.01 -2.35% -79.22%
Intra Cellular Therapies 45.25 -0.11 -0.24% 21.38%
J&J 164.53 -1.83 -1.10% 1.88%
Nektar Therapeutics 3.04 -0.17 -5.30% -83.07%
Pfizer 44.16 -0.27 -0.61% 2.67%
Rigel Pharmaceuticals 1.20 -0.02 -1.64% -66.94%
Sun Pharmaceuticals 930.70 12.85 1.40% 13.74%
Teva Pharmaceutical Industries Ltd 2,740.00 -46.00 -1.65% -13.62%
Xeris Pharmaceuticals Inc 1.59 0.01 0.63% -35.10%

Indexes Price Day Year
USND 10738 -314.13 -2.84% -25.68%

Acura Pharmaceuticals
Acura Pharmaceuticals, Inc. is a drug delivery company that is engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. The Company has discovered and developed approximately three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine tablets into methamphetamine.

Financials
Employees